Takeda Pharmaceutical Cash Flow Statement

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Year	2022	2021	2020	2019	2018	2017	2016
Net Income	317,017	230,059	376,005	44,241	135,192	186,886	114,940
Depreciation & Amortization	664,400	583,151	559,671	583,649	247,691	182,127	171,426
Share-Based Compensation	60,672	43,374	37,663	29,122	20,084	18,610	15,385
Other Operating Activities	121,033	406,944	239,279	239,508	-29,579	20,114	363
Operating Cash Flow	1,163,122	1,263,528	1,212,618	896,520	373,388	407,737	302,114
Operating Cash Flow Growth	-7.95%	4.20%	35.26%	140.10%	-8.42%	34.96%	-
Capital Expenditures	-139,695	-121,437	-64,753	-114,504	-26,960	-64,040	-59,031
Acquisitions	7,958	-21,476	530,388	456,656	-2,873,555	56,752	-524,739
Change in Investments	15,665	11,981	62,395	43,233	122,519	-40,215	-3,164
Other Investing Activities	-491,030	-67,193	-134,500	-93,266	-57,702	-45,839	-68,757
Investing Cash Flow	-607,102	-198,125	393,530	292,119	-2,835,698	-93,342	-655,691
Dividends Paid	-279,416	-283,665	-283,357	-282,582	-142,952	-141,893	-141,688
Share Issuance / Repurchase	-26,929	-77,531	-2,141	-3,737	-1,172	-18,756	-23,117
Debt Issued / Paid	-285,071	-600,477	-660,504	-586,090	3,141,997	-153,136	471,421
Other Financing Activities	-117,732	-108,592	-142,352	-132,804	-51,636	-12,441	-16,720
Financing Cash Flow	-709,148	-1,070,265	-1,088,354	-1,005,213	2,946,237	-326,226	289,896
Exchange Rate Effect	22,929	28,758	12,501	-21,766	-31,269	-4,565	-5,742
Net Cash Flow	-339,094	-145,285	316,107	-43,342	439,018	-41,714	-104,432
Free Cash Flow	1,023,427	1,142,091	1,147,865	782,016	346,428	343,697	243,083
Free Cash Flow Growth	-10.39%	-0.50%	46.78%	125.74%	0.79%	41.39%	-
Free Cash Flow Margin	25.41%	32.00%	35.90%	23.76%	16.52%	19.41%	14.03%
Free Cash Flow Per Share	330.06	365.27	368.43	249.84	221.08	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).